津药药业：酒石酸布托啡诺注射液获得药品注册证书

Core Viewpoint - Tianyao Pharmaceutical (600488) announced the approval of its subsidiary Tianyao Heping for the drug registration certificate of Butorphanol Tartrate Injection by the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating various cancer-related and postoperative pain [1] Company Summary - Tianyao Pharmaceutical's subsidiary Tianyao Heping has received regulatory approval for Butorphanol Tartrate Injection, which is intended for the treatment of cancer pain and postoperative pain [1]